Court To Hear Arguments In High-Stakes Suit Over Zyprexa
The case is highly unusual because the generics makers are attacking the validity of the research that led to the issuance of the drug’s underlying patent in 1993 by the U.S. Patent and Trademark Office. The patent gives Lilly exclusive right to sell Zyprexa in the U.S. until 2011.
Eli Lilly has sued three generics makers in the U.S. District Court for the...
To view the full article, register now.